Enveric Biosciences, Inc. (ENVB)

Nasdaq: ENVB · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 1996

Full chart Alerts Compare

Grade3.7

◀ Past 2.7● Present 4.5▶ Future 3.6

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Enveric Biosciences, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.7/10

◀ Past2.725% of the headline

● Present4.535% of the headline

▶ Future3.640% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.7/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.5/10

Has it survived what it has been through?

22 warning events since 2017; the latest 2025-10-23.

weight 22% of this tense · 5th percentile among 497 sector filers · read for itself

From the record

Enveric Biosciences, Inc.'s filings since 2017 show 22 warning events of 4 kinds: a debt default or acceleration notice (8-K item 2.04, 3 times, the latest 2018-10-05); a notice about its exchange listing (8-K item 3.01, 12 times, the latest 2025-10-23); an auditor change (8-K item 4.01, 6 times, the latest 2025-04-14); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.7/10

What has it actually done, year after year?

+18.5% a year over 5 filed years; profitable in 0 of 4.

weight 45% of this tense · 47th percentile among 323 sector filers · read for its customers

From the record

Enveric Biosciences, Inc.'s 5 filed years say what it did: revenue went from $20 million in fiscal 2015 to $40 million in fiscal 2019, up 18.5% a year; it rose in 2 of 4 years; the deepest fall was 18% from fiscal 2017 to fiscal 2019; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

revenue growth over the filed span18.5%top 42% of its family
the share of years revenue rosebottom 36% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak17.9%top 31% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

1.2/10

How has it treated the people who own it?

SI estimate 1.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 12th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 12% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Enveric Biosciences, Inc.'s shareholder treatment is put at 1.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 12% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.5/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

3.1/10

Is it financially healthy right now?

ROE -210%: lost 210¢ per shareholder dollar. Leverage 18%: owes 18¢ per asset dollar.

weight 45% of this tense · 31st percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Enveric Biosciences, Inc. lost about 210 cents for every dollar of shareholders' money. Leverage: it owed about 18 cents per dollar of assets, and net share issuance: its share count grew 698.7% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 29% of its family
return on equitybottom 15% of its family
the share count against the year beforebottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.6/10

How strong is its position in its industry?

top 44% of 315 in its family; net margin -6%.

weight 22% of this tense · 56th percentile among 315 sector filers · read for its customers

From the record

Enveric Biosciences, Inc.'s standing among 315 graded names in its industry family: revenue of $40 million in fiscal 2019 ranks in the top 48% by size; a net margin of -6% ranks in the top 28%; revenue growth of 3.4% a year over the last 3 filed years ranks in the bottom 43% (its annual reports).

What it rests on

revenue against the family$39.9Mtop 48% of its family
net margin-6.0%top 28% of its family
three-year revenue growth3.4%bottom 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

5.7/10

What are the people in charge doing?

top 43% of 315 in its family for leadership; chief executive since 2021.

weight 33% of this tense · 57th percentile among 315 sector filers · read for its shareholders

From the record

Enveric Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Tucker, Joseph Edward (Chief Executive Officer, as filed), filing under that title since 2021-09-27, 5.1 years (bottom 49% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 4.8 years (bottom 31%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 8%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge1 in three years among 8 peopletop 8% of its family
the median years the people in charge have filed4.8 yearsbottom 31% of its family
the chief executive's years on the record5.1 yearsbottom 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

3.6/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate

4.9/10

How much room does it have to grow?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 273 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue, so the desk assumes the typical reading of its industry family, the median of 273 members with one.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: family median, 273 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Enveric Biosciences, Inc.'s room to expand is put at 4.9 of 10 with a confidence of 20 of 100, because the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue, so the desk assumes the typical reading of its industry family, the median of 273 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Growth drivers

as filed

1.8/10

What could actually drive growth from here?

bottom 18% of 306 in its family for growth drivers.

weight 45% of this tense · 18th percentile among 306 sector filers · read for its customers

From the record

Enveric Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2019: revenue grew 3.4% a year over the last three filed years against 18.5% over all 5, slowing (bottom 28% of its family); the newest year grew -7.2% (bottom 30%); research spending grew -29.8% a year (bottom 13%); capital spending grew -83.5% a year (bottom 1%) (its annual reports). Enveric Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-15.1 points a yearbottom 28% of its family
the newest year's revenue growth-7.2%bottom 30% of its family
three-year growth of research spending-29.8%bottom 13% of its family
three-year growth of capital spending-83.5%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.5/10

Did its newest year beat what its own record pointed to?

top 45% of 233 in its family for expectations against reality.

weight 22% of this tense · 55th percentile among 233 sector filers · read for its shareholders

From the record

Enveric Biosciences, Inc.'s newest year against its own record: revenue of $40 million in fiscal 2019 came in 14.9% below the $47 million its prior three years' pace pointed to (bottom 35% of its family); net income of $2 million against a prior three-year average of $10 million (top 22%); a net margin of -6% against -21.9% before (top 46%) (its annual reports).

What it rests on

revenue against the prior three years' pace-14.9%bottom 35% of its family
net income against the prior three years' average+75%top 22% of its family
net margin against its prior average+15.8 pointstop 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ENVB · research, not advice